Posted on November 30, 2007 by jrowley
Senators Sam Brownback (R-Kan) and Mary Landrieu (D-La) introduced the Human-Animal Hybrid Prohibition Act to Congress last week that would make outlaws of scientists that create part human, part animal beings. According to a white paper published by Friends of the Earth, “A human-animal hybrid is an organism with both human and animal [...]
Filed under: ethics, politics, regulatory, stem cells | No Comments »
Posted on November 26, 2007 by jrowley
CellCyte Genetics Corporation recently announced that US Patent No 7,282,222 was issued, a patent which they have exclusive rights to. The press release states that the patent covers unique methods and compositions “to deliver and direct stem cells to target organs in the body”, including cardiac tissue.
The focus of the patent addresses cell retention at [...]
Filed under: Clinical Trials, Intellectual Property, Regenerative Medicine, cardiac regeneration, cell delivery, stem cells | 1 Comment »
Posted on November 21, 2007 by jrowley
I do not want to undermine the importance of the great work that was done in generating pluripotent stem cells from adult skin cells, but the only thing I think about when hearing this news is TIME and MONEY. I know I will be fielding questions from my friends and relatives over Thanksgiving weekend [...]
Filed under: Regenerative Medicine, stem cells | 2 Comments »
Posted on November 20, 2007 by jrowley
On November 15, 2007, Athersys announced in a press release that they had received a letter from the FDA giving the green light to start a Phase I safety study of MultiStem, their adult, allogeneic stem cell product. Athersys will start an open label, dose escalation trial to test their cells after bone marrow transplantation.
This [...]
Filed under: Athersys, Clinical Trials, FDA, MSCs, Osiris, Regenerative Medicine, adult stem cell, stem cells | Tagged: adult stem cells, Athersys, business model, stem cells clinical trials | 1 Comment »
Posted on November 20, 2007 by jrowley
An interesting study was published this week in the Journal of Neuroimmunology spurring a press release from Geron that stated “GERON’S HUMAN EMBRYONIC STEM (ES) CELL-BASED THERAPEUTIC FOR SPINAL CORD INJURY EVADES DIRECT ATTACK BY THE HUMAN IMMUNE SYSTEM”. The title is a little misleading since the cells really only evade immune cells in an [...]
Filed under: Advanced Cell Technology, Clinical Trials, Embyonic Stem Cells, Geron, Regenerative Medicine, regulatory, spinal cord injury, stem cells | Tagged: Clinical Trials, embryonic stem cells, immune response, spinal cord injury | No Comments »
Posted on November 17, 2007 by jrowley
I am not sure if you noticed, but the stem cell stocks haven’t been performing all that great in 2007, especially compared to technology companies like Apple or Google. So now seems as good a time as any to start a blog that will help to demystify the area of regenerative medicine and cell-based [...]
Filed under: Regenerative Medicine, Uncategorized | Tagged: regenerative medicine 2.0, stem cells | 1 Comment »
